Conditions: Parkinson Disease
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 4
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the effectiveness of neuroprotection from granulocyte colony-stimulating factor on Parkinson disease

Detailed description:
Parkinson's disease (PD) is the second most common neurodegenerative disease and the severity of PD still progress during the ensuing years. Currently, there is no promising medical or surgical treatment to abrogate the disease deterioration. Granulocyte colony-stimulating factor (G-CSF), one of hematopoietic growth factors, has been routinely used for hematologic disorders and stem cell harvest from normal subject. G-CSF also demonstrated neuroprotection for rodents PD model. We hypothesize G-CSF will exert the effectiveness of neuroprotection for PD patients.

Arms:
arm 1: high dose group: 3.3ug/kg/day for consecutive 5 days of each 60 day cycle (6 cycles) arm 2: low dose group: 1.65ug/kg/day for consecutive 5 days of each 60 day cycle (6 cycles) arm 3: Sodium Chloride (NaCl) 0.9 %

Interventions: intervention 1: G-CSF intervention 2: Placebo
Intervention descriptions: intervention 1: G-CSF(granulocyte-colony stimulating factor) is planned injected subcutaneously intervention 2: Sodium Chloride (NaCl) 0.9 %

Protocol document: